# Influence of a Zombie-like State of the Liver on Drugs and Its Medico-Legal Implications: A Scoping Review

**Authors:** Ivan Šoša

PMC · DOI: 10.3390/ph18060787 · Pharmaceuticals · 2025-05-24

## TL;DR

This review explores how 'zombie-like' liver cells affect drug responses and their implications in legal and medical contexts.

## Contribution

The paper introduces the medico-legal relevance of hepatocyte senescence and its secretory phenotype in drug administration.

## Key findings

- Hepatocyte senescence impacts drug metabolism and clinical interpretations.
- Senescent cells release SASP, which influences surrounding tissues and drug effects.
- The review highlights the importance of senescence in medico-legal and insurance assessments.

## Abstract

When cells remain permanently trapped in a particular cell cycle stage, they are in senescence. This also occurs in the liver. Such cells are often referred to as “zombie cells”, and an entire organ filled with these “zombie cells” is said to be in a “zombie-like” state, characterized by a lack of function. The senescence-associated secretory phenotype (SASP) encompasses the substances these “zombie cells” release, which can significantly affect nearby cells and tissues. While cellular senescence and SASP are related concepts, they are distinct. This scoping review aims to clarify the role of hepatocyte senescence and hepatocyte SASP in the administration of pharmaceuticals, as well as their relevance to medico-legal practice, disability claims, and insurance coverage. In this context, the effects of pharmaceuticals on senescent hepatocytes are discussed, particularly regarding the medico-legal implications of substances likely to be abused. In conclusion, hepatocyte senescence may be relevant in clinical or medico-legal work because it sheds a new light on interpreting clinical findings and expert witness statements.

## Full-text entities

- **Genes:** TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, GLB1 (galactosidase beta 1) [NCBI Gene 2720] {aka EBP, ELNR1, MPS4B}, CYP2D6 (cytochrome P450 family 2 subfamily D member 6 (gene/pseudogene)) [NCBI Gene 1565] {aka CPD6, CYP2D, CYP2D7AP, CYP2D7BP, CYP2D7P2, CYP2D8P2}, IL22 (interleukin 22) [NCBI Gene 50616] {aka IL-21, IL-22, IL-D110, IL-TIF, ILTIF, TIFIL-23}, CYP4F3 (cytochrome P450 family 4 subfamily F member 3) [NCBI Gene 4051] {aka CPF3, CYP4F, CYPIVF3, LTB4H}, ACSM3 (acyl-CoA synthetase medium chain family member 3) [NCBI Gene 6296] {aka SA, SAH}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, IL1A (interleukin 1 alpha) [NCBI Gene 3552] {aka IL-1 alpha, IL-1A, IL1, IL1-ALPHA, IL1F1}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, CBX1 (chromobox 1) [NCBI Gene 10951] {aka CBX, HP1-BETA, HP1Hs-beta, HP1Hsbeta, Hp1beta, M31}, CXCR2 (C-X-C motif chemokine receptor 2) [NCBI Gene 3579] {aka CD182, CDw128b, CMKAR2, IL8R2, IL8RA, IL8RB}, CAV1 (caveolin 1) [NCBI Gene 857] {aka BSCL3, CGL3, LCCNS, MSTP085, PPH3, VIP21}, FGF2 (fibroblast growth factor 2) [NCBI Gene 2247] {aka BFGF, FGF-2, FGFB, HBGF-2}, CAVIN1 (caveolae associated protein 1) [NCBI Gene 284119] {aka CAVIN, CGL4, FKSG13, PTRF, cavin-1}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, CYP3A4 (cytochrome P450 family 3 subfamily A member 4) [NCBI Gene 1576] {aka CP33, CP34, CYP3A, CYP3A3, CYPIIIA3, CYPIIIA4}, CCNA2 (cyclin A2) [NCBI Gene 890] {aka CCN1, CCNA}, CNR1 (cannabinoid receptor 1) [NCBI Gene 1268] {aka CANN6, CB-R, CB1, CB1A, CB1K5, CB1R}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, IL13 (interleukin 13) [NCBI Gene 3596] {aka IL-13, P600}, CYP2C9 (cytochrome P450 family 2 subfamily C member 9) [NCBI Gene 1559] {aka CPC9, CYP2C, CYP2C10, CYPIIC9, P450-2C9, P450IIC9}, MIR29A (microRNA 29a) [NCBI Gene 407021] {aka MIRN29, MIRN29A, hsa-mir-29, hsa-mir-29a, miRNA29A, mir-29a}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, MIR146A (microRNA 146a) [NCBI Gene 406938] {aka MIRN146, MIRN146A, miR-146a, miRNA146A}, IL4 (interleukin 4) [NCBI Gene 3565] {aka BCGF-1, BCGF1, BSF-1, BSF1, IL-4}, SLCO1B1 (solute carrier organic anion transporter family member 1B1) [NCBI Gene 10599] {aka HBLRR, LST-1, OATP-C, OATP1B1, OATP2, OATPC}, CDKN1A (cyclin dependent kinase inhibitor 1A) [NCBI Gene 1026] {aka CAP20, CDKN1, CIP1, MDA-6, P21, SDI1}, CDKN2A (cyclin dependent kinase inhibitor 2A) [NCBI Gene 1029] {aka ARF, CAI2, CDK4I, CDKN2, CMM2, INK4}, ABCB1 (ATP binding cassette subfamily B member 1) [NCBI Gene 5243] {aka ABC20, CD243, CLCS, ENPAT, GP170, MDR1}, CNR2 (cannabinoid receptor 2) [NCBI Gene 1269] {aka CB-2, CB2, CX5}, CDH5 (cadherin 5) [NCBI Gene 1003] {aka 7B4, CD144}, PGP (phosphoglycolate phosphatase) [NCBI Gene 283871] {aka AUM, G3PP, PGPase}
- **Diseases:** SASP (MESH:D008579), viral hepatitis (MESH:D014777), mitochondrial dysfunction (MESH:D028361), injuries (MESH:D014947), impaired liver function (MESH:D008107), Inflammation (MESH:D007249), fibrosis (MESH:D005355), rhabdomyolysis (MESH:D012206), pulmonary edema (MESH:D011654), toxic injury (MESH:D064420), liver fibrosis (MESH:D008103), acute liver injury (MESH:D017114), blood loss (MESH:D016063), Substance Abuse (MESH:D019966), CVD (MESH:D002318), diabetes (MESH:D003920), endothelial dysfunction (MESH:D014652), cancer (MESH:D009369), liver damage (MESH:D056486), chronic liver injury (MESH:D056487), cardiac injury (MESH:D006331), liver injury (MESH:D017093), bruising (MESH:D003288), bleeding (MESH:D006470), tissue damage (MESH:D017695), hepatocellular carcinoma (MESH:D006528)
- **Chemicals:** Opiate (MESH:D053610), olanzapine (MESH:D000077152), NPSs (-), heroin (MESH:D003932), DMT (MESH:D004130), nicotine (MESH:D009538), Cocaine (MESH:D003042), LSD (MESH:D008238), lipid (MESH:D008055), glucose (MESH:D005947), quetiapine (MESH:D000069348), Psilocybin (MESH:D011562), cannabinoids (MESH:D002186), ROS (MESH:D017382), warfarin (MESH:D014859), Tenovin-1 (MESH:C000594735), alcohol (MESH:D000438)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12196361/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12196361/full.md

## References

120 references — full list in the complete paper: https://tomesphere.com/paper/PMC12196361/full.md

---
Source: https://tomesphere.com/paper/PMC12196361